Date and Time: June 2 and 3, 2004, from 8 a.m. to 5 p.m.

Location: Food and Drug Administration, Center for Drug Evaluation and Research Advisory Committee Conference Room, 5630 Fishers Lane, rm. 1066, Rockville, MD.

Agenda:

• On June 2, 2004, the committee will discuss trial design and endpoints for drugs for chronic gout, including new drug application (NDA) 21-740, oxypurinol (proposed tradename, Oxiprim), Cardiome.

• On June 3, 2004, the committee will discuss trial design and endpoints for drugs for acute
  gout, including NDA 21-389, etoricoxib (proposed tradename, Arcoxia),
  Merck.

Federal Register Notice for Meeting

Contact Person: Kimberly Littleton Topper, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 301-827-7001,  Fax: 301-827-6801, email: topperk@cder.fda.gov

Please call the Information Line for up-to-date information on this meeting,
1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512532.

Back to Top     Analgesia and Anti-inflammatory Drugs

Date created: April 29, 2004

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA/Center for Drug Evaluation and Research